Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

Dendritic cell-based vaccine in advanced melanoma

Ridolfi, L., Petrini, M., Fiammenghi, L., Granato, A. M., Ancarani, V., Pancisi, E., Brolli, C., Selva, M., Scarpi, E., Valmorri, L., et al. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834b58fa · Cited by 40

Dok1 and Dok2 proteins regulate natural killer cell development and function

Celis‐Gutierrez, J., Boyron, M., Walzer, T., Pandolfi, P. P., Jonjić, S., Olive, D., Dalod, M., Vivier, É., & Nunès, J. A. (2014) · The EMBO Journal · doi:10.15252/embj.201387404 · Cited by 40

Toll-Like Receptor Agonists: Current Status and Future Perspective on their Utility as Adjuvants in Improving Antic Ancer Vaccination Strategies

Baxevanis, C. N., Voutsas, I. F., & Tsitsilonis, O. (2013) · Immunotherapy · doi:10.2217/imt.13.24 · Cited by 43

Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

Heppner, B. I., Loibl, S., & Denkert, C. (2016) · Breast Care · doi:10.1159/000444357 · Cited by 40

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme

Lee, M., Park, C., Woo, J., Kim, J.-H., Kho, I., Nam, D., Park, W., Kim, Y.-S., Kong, D., Lee, H. W., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00555 · Cited by 41

Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC

Ryan, S.-L., Beard, S., Barr, M. P., Umezawa, K., Heavey, S., Godwin, P., Gray, S. G., Cormican, D., Finn, S. P., Gately, K. A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.006 · Cited by 40

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response

Toffoli, E. C., Sheikhi, A., Höppner, Y. D., de Kok, P., Yazdanpanah‐Samani, M., Spanholtz, J., Verheul, H. M. W., van der Vliet, H. J., & de Gruijl, T. D. (2021) · Cancers · doi:10.3390/cancers13040711 · Cited by 42

Repositioning of Antiparasitic Drugs for Tumor Treatment

Li, Y., Zheng, Z., Liu, Q., Lu, X., Zhou, D., Zhang, J., Zheng, H., & Dai, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670804 · Cited by 42

Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics

Říhová, B., Kovář, L., Kovář, M., & Hovorka, O. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.10.006 · Cited by 40

Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients

Chan, M. S. M., Wang, L. Q., Felizola, S. J. A., Ueno, T., Toi, M., Loo, W. T. Y., Chow, L. W., Suzuki, T., & Sasano, H. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.10439 · Cited by 40

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC

Lion, E., Anguille, S., Berneman, Z. N., Smits, E., & Tendeloo, V. F. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020952 · Cited by 39

Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment

Green, T. L., Cruse, J. M., & Lewis, R. E. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.06.013 · Cited by 39

Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells

Sakai, H., Kokura, S., Ishikawa, T., Tsuchiya, R., Okajima, M., Matsuyama, T., Adachi, S., Katada, K., Kamada, K., Uchiyama, K., et al. (2012) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.12-60 · Cited by 39

Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial

Ridolfi, L. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1099 · Cited by 40

Immunotherapy of Breast Cancer

Criscitiello, C., & Curigliano, G. (2015) · Progress in tumor research · doi:10.1159/000437183 · Cited by 39

Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators

Wu, J., Jordan, M., & Waxman, D. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2597-2 · Cited by 44

Dendritic Cells: Location, Function, and Clinical Implications

Castell-Rodríguez, A. E., Piñón-Zárate, G., Herrera-Enríquez, M. Á., Jarquín-Yáñez, K., & Medina-Solares, I. (2017) · InTech eBooks · doi:10.5772/intechopen.68352 · Cited by 46

The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment

Macdonald, F., & Zaiss, D. M. W. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00575 · Cited by 40

DNA-Binding Anticancer Drugs: One Target, Two Actions

Baguley, B. C., Drummond, C. J., Chen, Y. Y., & Finlay, G. J. (2021) · Molecules · doi:10.3390/molecules26030552 · Cited by 39

Recent Progress of Alkyl Radicals Generation‐Based Agents for Biomedical Applications

Lee, K., Wan, Y., Li, X., Cui, X., Li, S., & Lee, C. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100055 · Cited by 41

Contribution du système immunitaire à l’efficacité des chimiothérapies anticancéreuses

Zitvogel, L., Tesnière, A., Apétoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32694-9 · Cited by 43

The Invisible Arm of Immunity in Common Cancer Chemoprevention Agents

Marzbani, E., Inatsuka, C., Lu, H., & Disis, M. L. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0036 · Cited by 39

Tumor lysate-loaded biodegradable microparticles as cancer vaccines

Joshi, V. B., Geary, S. M., Gross, B., Wongrakpanich, A., Norian, L. A., & Salem, A. K. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.851606 · Cited by 39

Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy

Deng, C., Jia, M., Wei, G., Tan, T., Fu, Y. S., Gao, H., Sun, X., Zhang, Q., Gong, T., & Zhang, Z. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00932 · Cited by 39

Data-Driven Mathematical Model of Osteosarcoma

Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39

Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity

Multhoff, G., Pockley, A. G., Streffer, C., & Gaipl, U. S. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306666 · Cited by 38

Beyond the M‐ CSF receptor – novel therapeutic targets in tumor‐associated macrophages

Bonelli, S., Geeraerts, X., Bolli, E., Keirsse, J., Kiss, M., Antunes, A. R. P., Damme, H. V., Vlaminck, K. D., Movahedi, K., Laoui, D., et al. (2017) · FEBS Journal · doi:10.1111/febs.14202 · Cited by 37

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts

Stoll, G., Pol, J. G., Soumelis, V., Zitvogel, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484980 · Cited by 38

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

Rodallec, A., Sicard, G., Fanciullino, R., Benzekry, S., Lacarelle, B., Milano, G. A., & Ciccolini, J. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1540588 · Cited by 39

Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy

Russo, L., Maltese, A., Betancourt, L., Romero, G., Cialoni, D., la Fuente, L. D., Gutierrez, M., Ruiz, A., Agüero, E., & Hernandez, S. F. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.01.222 · Cited by 38

Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin

Pusuluri, A., Krishnan, V., Wu, D., Shields, C. W., Wang, L., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10129 · Cited by 38

Adjuvant immunotherapy for non-small cell lung cancer

Tucker, Z. C. G., Laguna, B. A., Moon, E. K., & Singhal, S. K. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.008 · Cited by 38

Assessment of mechanism involved in the apoptotic and anti-cancer activity of Quercetin and Quercetin-loaded chitosan nanoparticles

Doğan, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01820-x · Cited by 37

Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma

Tanaka, T., Masuda, A., Inoue, J., Hamada, T., Ikegawa, T., Toyama, H., Sofue, K., Shiomi, H., Sakai, A., Kobayashi, T., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-022-01939-8 · Cited by 36

Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules

Piras, V., Hayashi, K., Tomita, M., & Selvarajoo, K. (2011) · Scientific Reports · doi:10.1038/srep00144 · Cited by 37

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

Sasada, T., Komatsu, N., Suekane, S., Yamada, A., Noguchi, M., & Itoh, K. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.013 · Cited by 37

Modelling Physiological and Pharmacological Control on Cell Proliferation to Optimise Cancer Treatments

Clairambault, J. (2009) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20094302 · Cited by 38

Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients

Mross, K. B., & Steinbild, S. (2012) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-1-32 · Cited by 36

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

Triulzi, T., Cecco, L. D., Sandri, M. F., Prat, A., Giussani, M., Paolini, B., Carcangiu, M. L., Canevari, S., Bottini, A., Balsari, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4405 · Cited by 37

Omics for Investigating Chitosan as an Antifungal and Gene Modulator

López-Moya, F., & Lopez-Llorca, L. (2016) · Journal of Fungi · doi:10.3390/jof2010011 · Cited by 34

Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation

Greil, R., Hutterer, E., Hartmann, T. N., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0155-9 · Cited by 37

Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion

Choi, J. U., Maharjan, R., Pangeni, R., Jha, S. K., Lee, N. K., Kweon, S., Lee, H. K., Chang, K.-Y., Choi, Y. K., Park, J. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.012 · Cited by 39

Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA

Nguyen, H. T., Phung, C. D., Tran, T. H., Pham, T. T., Pham, L. M., Nguyen, T. T., Jeong, J., Choi, H., Ku, S., Yong, C. S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.034 · Cited by 37

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy

Gu, Y., Zhang, P., Wang, J., Lin, C., Liu, H., Li, H., He, H., Li, R., Zhang, H., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03326-x · Cited by 37

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

Bellone, M., Mondino, A., & Corti, A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.003 · Cited by 37

The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers

Karn, T., Pusztai, L., Rody, A., Holtrich, U., & Becker, S. (2015) · Current Cancer Drug Targets · doi:10.2174/156800961508151001101209 · Cited by 39

Sulphur Containing Heterocyclic Compounds as Anticancer Agents

Sharma, V., Kaur, B., Singh, G., & Singh, I. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666221221143918 · Cited by 36

Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells

Liu, P., Zhao, L., Zitvogel, L., Kepp, O., & Kroemer, G. (2023) · Immunological Reviews · doi:10.1111/imr.13269 · Cited by 41

A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy

Chung, D., Shin, H.-J., & Hong, Y.-K. (2014) · Journal of Immunology Research · doi:10.1155/2014/326545 · Cited by 35

Immunotherapy in Ovarian Cancer

Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36

LvHemB1, a novel cationic antimicrobial peptide derived from the hemocyanin of Litopenaeus vannamei, induces cancer cell death by targeting mitochondrial voltage-dependent anion channel 1

Liu, S., Aweya, J. J., Zheng, L., Zheng, Z., Huang, H., Wang, F., Yao, D., Ou, T., & Zhang, Y. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09588-y · Cited by 36

Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology

Criscitiello, C., Guerini‐Rocco, E., Viale, G., Fumagalli, C., Sajjadi, E., Venetis, K., Piciotti, R., Invernizzi, M., Malapelle, U., & Fusco, N. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706144112 · Cited by 36

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy

Groenewold, M. D., Olthof, C. G., & Bosch, D. J. (2021) · BJA Education · doi:10.1016/j.bjae.2021.08.002 · Cited by 36

Immunology and immunotherapy in breast cancer

Семиглазов, В. Ф., Tseluyko, A. I. T., Галимовна, К. А., Artemyeva, A. S., Криворотько, П. В., & Donskih, R. V. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0597 · Cited by 36

Dual-targeting delivery system for selective cancer cell death and imaging

Tian, X., Baek, K. H., & Shin, I. (2012) · Chemical Science · doi:10.1039/c2sc21777e · Cited by 37

Prognostic value of HMGB 1 in early breast cancer patients under neoadjuvant chemotherapy

Exner, R., Sachet, M., Arnold, T., Zinn-Zinnenburg, M., Michlmayr, A., Dubsky, P. C., Bartsch, R., Steger, G. G., Gnant, M., Bergmann, M. M., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.827 · Cited by 36

FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer

Rožková, D., Tišerová, H., Fucikova, J. P., Lašťovička, J., Podrazil, M., Ulčová, H., Budínský, V., Prausová, J., Linke, Z., Minárik, I., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.001 · Cited by 36

Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment

Kim, D., Pyo, A., Yun, M., Thangam, R., You, S.-H., Zhang, Y., Jung, Y.-R., Nguyen, D.-H., Venu, A., Kim, H. S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245290 · Cited by 35

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Fabian, K. P., Kowalczyk, J. T., Reynolds, S. T., & Hodge, J. W. (2022) · Cells · doi:10.3390/cells11233826 · Cited by 37

Tailor‐Made Autophagy Cascade Amplification Polymeric Nanoparticles for Enhanced Tumor Immunotherapy

Long, X., Wang, H., Yan, J., Li, Y., Dong, X. Z., Tian, S., Sun, Y., Luo, K., He, B., & Liang, Y. (2023) · Small · doi:10.1002/smll.202207898 · Cited by 37

Polylysine-modified near-infrared-emitting carbon dots assemblies: Amplification of tumor accumulation for enhanced tumor photothermal therapy

Li, Z., Cheng, H., Wang, B., Wang, L., Wu, J., Zhang, B., Tang, Z., & Qu, S. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.04.153 · Cited by 35

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

McMillin, D. W., Delmore, J. E., Negri, J. M., Vanneman, M. W., Koyama, S., Schlossman, R. L., Munshi, N. C., Laubach, J. P., Richardson, P. G. G., Dranoff, G., et al. (2012) · Blood · doi:10.1182/blood-2011-04-348490 · Cited by 35

Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions

Nardin, A., Wong, W., Tow, C., Molina, T. J., Tissier, F., Audebourg, A., Garcette, M., Caignard, A., Avril, M., Abastado, J., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.128 · Cited by 42

Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms

Jahangir, A., Chandra, D., Quispe‐Tintaya, W., Singh, M., Selvanesan, B. C., & Gravekamp, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342025 · Cited by 35

Combination therapies and intra-tumoral competition: Insights from mathematical modeling

Piretto, E., Delitala, M. E., & Ferraro, M. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.03.014 · Cited by 34

Non-Thermal Plasma Application in Tumor-Bearing Mice Induces Increase of Serum HMGB1

Troitskaya, O. S., Патракова, Е. А., Biryukov, M., Varlamov, M., Гугин, П. П., Milakhina, E. V., Richter, V. A., Schweigert, I. V., Zakrevsky, D. E., & Koval, O. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145128 · Cited by 36

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

Wingerter, A., Malki, K. E., Sandhoff, R., Seidmann, L., Wagner, D., Lehmann, N., Vewinger, N., Frauenknecht, K. B. M., Sommer, C., Traub, F., et al. (2021) · Cancers · doi:10.3390/cancers13030520 · Cited by 36

Fighting cancers from within: augmenting tumor immunity with cytokine therapy

Pellegrini, M., Mak, T. W., & Ohashi, P. S. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.003 · Cited by 35

The implication and potential applications of high-mobility group box 1 protein in breast cancer

Moonindranath, S., & Shen, H. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.36 · Cited by 35

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Buisseret, L., Loirat, D., Aftimos, P. G., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Gonçalvès, A., Ghiringhelli, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42744-y · Cited by 34

The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer

Larson, A. C., Doty, K. R., & Solheim, J. C. (2024) · Cancer Medicine · doi:10.1002/cam4.7287 · Cited by 35

Rational Design of a Hetero-multinuclear Gadolinium(III)–Copper(II) Complex: Integrating Magnetic Resonance Imaging, Photoacoustic Imaging, Mild Photothermal Therapy, Chemotherapy and Immunotherapy of Cancer

Man, X., Li, W., Zhu, M., Li, S., Xu, G., Zhang, Z., Liang, H., & Yang, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01273 · Cited by 34

Contribution of the immune system to the chemotherapeutic response

McDonnell, A. M., Nowak, A. K., & Lake, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0246-z · Cited by 34

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma

Tomimaru, Y., Mishra, S., Safran, H. P., Charpentier, K. P., Martin, W. D., Groot, A. S. D., Gregory, S. H., & Wands, J. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.037 · Cited by 34

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

Vargas, T. R., & Apétoh, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01181 · Cited by 37

Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy

Parker, N., Correia, N., Crossley, B., Buckland, M. E., Howell, V. M., & Wheeler, H. (2013) · Translational Oncology · doi:10.1593/tlo.13553 · Cited by 34

Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines

Wen, C.-C., Chen, H., Chen, S.-S., Huang, L., Chang, W., Wei, W., Chou, L., Arulselvan, P., Wu, J., Kuo, S., et al. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-44 · Cited by 36

Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer TLRs in T-reg Cells of HNSCC Patients

Wild, C. A. (2010) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archoto.2010.195 · Cited by 34

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Liefaard, M. C., van der Voort, A., van Seijen, M., Thijssen, B., Sanders, J., Vonk, S., Mittempergher, L., Bhaskaran, R., de Munck, L., van Leeuwen‐Stok, A. E., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00636-4 · Cited by 33

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors

Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Tesone, A. J., Perales‐Puchalt, A., Nguyen, J. M., Sarmin, F., Sheen, M. R., Jeng, E. K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2808 · Cited by 34

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host

Modica, M. D., Tagliabue, E., & Triulzi, T. (2017) · Disease Markers · doi:10.1155/2017/7849108 · Cited by 33

Big Data Approaches for Modeling Response and Resistance to Cancer Drugs

Jiang, P., Sellers, W. R., & Liu, X. S. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013350 · Cited by 32

Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy

Malone, M. K., Smrekar, K., Park, S., Blakely, B., Walter, A. B., Nasta, N., Park, J., Considine, M., Danilova, L., Pandey, N. B., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1739484 · Cited by 33

Immunogenic chemotherapy in two mouse colon cancer models

Taniura, T., Iida, Y., Kotani, H., Ishitobi, K., Tajima, Y., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14624 · Cited by 33

Molecular Heterogeneity and Evolution in Breast Cancer

Caswell-Jin, J. L., Lorenz, C., & Curtis, C. N. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060220-014137 · Cited by 32

Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity

Lai, V., Neshat, S. Y., Rakoski, A. I., Pitingolo, J., & Doloff, J. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113920 · Cited by 33

Evidence of immunogenic cancer cell death induced by honey-processed Astragalus polysaccharides in vitro and in vivo

Sha, X., Xu, X., Liao, S., Chen, H., & Rui, W. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112948 · Cited by 36

Immune-based combination therapy for esophageal cancer

Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 33

Naringin ameliorates 5-fluorouracil induced cardiotoxicity: An insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters

Gui, Y., Famurewa, A. C., & Olatunji, O. J. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102035 · Cited by 33

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

Michlmayr, A., Bachleitner‐Hofmann, T., Baumann, S., Marchetti‐Deschmann, M., Weichselbraun, I., Burghuber, C. K., Pluschnig, U., Bartsch, R., Graf, A. C., Greil, R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605909 · Cited by 33

S-1 plus CIK as second-line treatment for advanced pancreatic cancer

Wang, M., Sheng-bin, S., Qi, J.-L., Tang, X., & Tian, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0747-9 · Cited by 33

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma

Pessina, S., Cantini, G., Kapetis, D., Cazzato, E., Ianni, N. D., Finocchiaro, G., & Pellegatta, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108513 · Cited by 33

Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatmentPreprint

Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 35

Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight

Damare, R., Engle, K., & Kumar, G. (2024) · Phytotherapy Research · doi:10.1002/ptr.8166 · Cited by 32

Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma

Anraku, M., Tagawa, T., Wu, L., Yun, Z., Keshavjee, S. H., Li, Z., Johnston, M. R., & de Perrot, M. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900437 · Cited by 32

Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML

Lichtenegger, F. S., Lorenz, R., Gellhaus, K., Hiddemann, W., Beck, B., & Subklewe, M. S. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.05.014 · Cited by 32

Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells

Paroli, M., Bellati, F., Videtta, M., Focaccetti, C., Mancone, C., Donato, T., Antonilli, M., Perniola, G., Accapezzato, D., Napoletano, C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28515 · Cited by 32

Role of Myeloid-Derived Suppressor Cells in Tumor Immunotherapy

Martin, F., Apétoh, L., & Ghiringhelli, F. (2011) · Immunotherapy · doi:10.2217/imt.11.154 · Cited by 33

Matrices for combined delivery of proteins and synthetic molecules

Gilmore, K. A., Lampley, M. W., Boyer, C. A., & Harth, E. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.018 · Cited by 32

Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells

Kuczma, M., Ding, Z., & Zhou, G. (2016) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016017507 · Cited by 32

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328